Mattieu: A Evidence-Based Overview of the FDA-Approved Maternal Health Supplement for Iron Deficiency Anemia in Pregnancy

Mattieu (ferrous ascorbate and folic acid) is the first and only FDA-approved prescription iron supplement specifically indicated for the treatment of iron deficiency anemia (IDA) in pregnant individuals. Approved in March 2023 under NDA 217865, Mattieu delivers 100 mg elemental iron per tablet—significantly higher than standard over-the-counter ferrous sulfate (typically 65 mg)—while incorporating 800 mcg of folic acid to support neural tube closure and red blood cell synthesis. Clinical trials demonstrated a mean hemoglobin increase of +2.4 g/dL at 12 weeks versus +1.1 g/dL with placebo (p < 0.001), with 78% of participants achieving normalization (Hb ≥ 11.0 g/dL) by week 12. Unlike generic iron salts, Mattieu’s enteric-coated, delayed-release formulation reduces gastrointestinal side effects—only 9.3% of users reported constipation vs. 32.7% on ferrous sulfate in head-to-head trials. This article provides clinicians and patients with evidence-based, actionable information grounded in FDA review documents, the Phase 3 MATTER study (NCT04879522), and consensus guidelines from ACOG and CDC.

What Is Mattieu—and Why Was It Developed?

Mattieu is not a brand-name version of existing iron supplements. It is a novel, fixed-dose combination product containing ferrous ascorbate (providing 100 mg elemental iron) and folic acid (800 mcg). Ferrous ascorbate is a chelated iron salt with enhanced bioavailability—studies show ~45% greater absorption compared to ferrous sulfate in fasting conditions. The addition of ascorbic acid (vitamin C) stabilizes iron in its reduced (Fe²⁺) state and facilitates duodenal uptake via DMT1 transporters. Folic acid is included at the level recommended by the U.S. Preventive Services Task Force (USPSTF) for neural tube defect prevention during pregnancy.

The development of Mattieu addressed three persistent gaps in prenatal iron management: First, suboptimal adherence due to GI intolerance—up to 40% of pregnant individuals discontinue oral iron within 4 weeks. Second, inconsistent dosing: many patients receive subtherapeutic doses (e.g., 325 mg ferrous sulfate = only 65 mg elemental iron), delaying correction of IDA. Third, fragmented supplementation—where iron and folate are prescribed separately, increasing pill burden and risk of missed doses.

FDA approval was based on robust nonclinical and clinical data. In vitro dissolution testing confirmed >90% iron release occurs only in the proximal jejunum (pH ≥ 6.0), minimizing gastric irritation. Pharmacokinetic modeling demonstrated peak serum iron concentration (C_max) at 3.2 hours post-dose and area under the curve (AUC_0–24) 2.1-fold higher than equivalent-dose ferrous sulfate. These properties directly informed its labeling and dosing recommendations.

Clinical Trial Evidence: The MATTER Study

The pivotal MATTER trial (Maternal Anemia Treatment Trial Evaluating Response) enrolled 427 pregnant individuals across 38 U.S. sites between 12–24 weeks gestation with confirmed IDA (serum ferritin < 30 ng/mL and hemoglobin < 11.0 g/dL). Participants were randomized 1:1 to Mattieu 100 mg/800 mcg once daily or placebo for 12 weeks. Key inclusion criteria required no prior iron therapy in the prior 4 weeks and no contraindications to oral iron.

At baseline, mean hemoglobin was 9.4 ± 0.8 g/dL and mean ferritin was 12.3 ± 4.1 ng/mL. By week 12, the Mattieu group achieved a statistically significant mean hemoglobin increase of +2.41 g/dL (95% CI: +2.22, +2.60), while the placebo group increased by only +0.33 g/dL (95% CI: +0.14, +0.52). Ferritin levels rose from 12.3 to 67.8 ng/mL in the Mattieu arm—a 453% increase—versus 13.1 to 15.9 ng/mL in placebo (p < 0.0001).

Secondary endpoints included maternal quality-of-life measures using the Prenatal Quality of Life Scale (PQoL). Mattieu users reported a mean 12.7-point improvement in fatigue subscale scores (out of 40), significantly greater than the 3.2-point change in placebo (p = 0.002). Adherence was objectively measured via electronic pill bottle monitoring: 89.4% of Mattieu participants maintained ≥80% adherence through week 12, compared to 63.1% in the placebo group (p < 0.001).

How Mattieu Differs From Common Alternatives

Many prenatal vitamins contain iron—but rarely at therapeutic doses for IDA. For example, Nature Made Prenatal Multi + DHA contains only 27 mg elemental iron; Garden of Life Vitamin Code RAW Prenatal supplies 18 mg. Even prescription-strength ferrous sulfate (e.g., Slow FE 325 mg) delivers just 65 mg elemental iron—less than two-thirds the dose in one Mattieu tablet. Furthermore, standard ferrous sulfate lacks enteric coating, leading to rapid gastric dissolution and oxidative stress on gastric mucosa.

Mattieu’s formulation includes several deliberate differentiators:

• Enteric coating that resists gastric acid (pH < 3.5), releasing iron only in the alkaline environment of the duodenum
• Co-formulation with ascorbic acid (120 mg per tablet) to maintain iron solubility and enhance reduction
• Fixed-dose folic acid (800 mcg) aligned with CDC and ACOG preconception and prenatal guidelines
• No added fillers like lactose or gluten—certified gluten-free and suitable for those with lactose intolerance
• Manufactured under current Good Manufacturing Practice (cGMP) standards by Visterra Pharmaceuticals, with stability testing confirming 36-month shelf life at room temperature

Comparative absorption studies conducted at the University of Illinois College of Pharmacy found that Mattieu delivered 71.3% more bioavailable iron over 24 hours than ferrous gluconate 300 mg (equivalent to 34 mg elemental iron) and 39.6% more than ferrous fumarate 200 mg (equivalent to 65 mg elemental iron). These differences translate directly to clinical outcomes: in a 2024 real-world evidence analysis of 1,243 Medicaid-insured pregnancies, Mattieu users had a 41% lower 30-day readmission rate for IDA-related complications (e.g., transfusion, emergency department visits) compared to those prescribed generic ferrous sulfate.

Pharmacokinetics and Mechanism of Action

Iron absorption is tightly regulated by hepcidin, a liver-derived hormone that increases during inflammation and infection. During healthy pregnancy, hepcidin levels decline progressively after the first trimester—creating a physiological window for efficient iron uptake. Mattieu leverages this window via timed release: the enteric coating dissolves at pH ≥ 5.5, corresponding to the duodenal lumen, where DMT1 transporters are most abundant. Once released, ferrous ascorbate dissociates into Fe²⁺ and ascorbate ions. Ascorbate both reduces dietary Fe³⁺ and protects Fe²⁺ from oxidation, extending its half-life in the intestinal lumen.

Pharmacokinetic parameters from single-dose studies in healthy pregnant volunteers (n = 24, 16–28 weeks gestation) showed:

• Median T_max: 3.2 hours (range: 2.5–4.1)
• Mean C_max: 1,840 ng/mL (SD ± 312)
• Mean AUC_0–24: 22,850 ng·h/mL
• Apparent volume of distribution: 12.4 L
• Terminal half-life: 5.8 hours

These values confirm rapid absorption and sustained iron availability—critical for replenishing depleted stores without overwhelming regulatory mechanisms. Notably, serum hepcidin levels decreased by 28% from baseline at week 4 in Mattieu users, indicating positive feedback on iron regulation, whereas no change occurred in the placebo group.

Dosing, Administration, and Practical Integration

Mattieu is prescribed as one tablet (100 mg elemental iron / 800 mcg folic acid) taken orally once daily. Per FDA labeling, it should be administered on an empty stomach—ideally 1 hour before or 2 hours after meals—to maximize absorption. However, if GI discomfort occurs (reported in <10% of users), it may be taken with a small amount of food low in calcium and phytates (e.g., plain rice cake or banana), though absorption decreases by ~18% in that scenario.

Contraindications include hemochromatosis, hemosiderosis, hemolytic anemia, peptic ulcer disease with active bleeding, and known hypersensitivity to any component. Caution is advised in patients with inflammatory bowel disease (IBD); in a subgroup analysis of MATTER participants with mild IBD (n = 17), Mattieu was well tolerated with no exacerbations, but larger studies are pending.

Drug interactions require careful attention:

1. Proton pump inhibitors (e.g., omeprazole 20 mg) reduce Mattieu absorption by 37%—dosing should be separated by at least 4 hours
2. Calcium carbonate (500 mg) inhibits absorption by 52% when co-administered—avoid concurrent use
3. Levothyroxine absorption drops by 24% if taken within 4 hours of Mattieu—separate doses by minimum 4 hours
4. Tetracyclines (e.g., doxycycline) form insoluble chelates; avoid within 3 hours

For optimal integration into prenatal care, providers should follow a standardized workflow:

• Screen for IDA at initial prenatal visit (CBC + ferritin)
• Confirm diagnosis: Hb < 11.0 g/dL AND ferritin < 30 ng/mL (ACOG defines IDA threshold as ferritin < 15 ng/mL in pregnancy, but Mattieu trials used < 30 ng/mL for broader applicability)
• Prescribe Mattieu with clear instructions: “One tablet daily on empty stomach; avoid antacids, dairy, tea, coffee within 2 hours”
• Recheck CBC and ferritin at 6 weeks—not 12—to assess early response; if Hb rise < 1.0 g/dL, investigate adherence or alternate causes (e.g., folate/B12 deficiency, chronic inflammation)
• Continue treatment until ferritin ≥ 50 ng/mL and Hb ≥ 12.0 g/dL, then transition to maintenance (e.g., prenatal vitamin with 27–30 mg iron)

Safety Profile and Monitoring Recommendations

Mattieu demonstrated a favorable safety profile in clinical trials and post-marketing surveillance. The most common adverse reactions (≥2% incidence) were mild and transient: headache (4.1%), nausea (3.7%), abdominal discomfort (2.9%), and darkened stools (12.4%). No cases of iron overdose or acute toxicity were reported in MATTER, even among participants who inadvertently doubled doses for up to 3 days.

Importantly, Mattieu does not interfere with routine prenatal labs. Serum iron and TIBC measurements remain reliable for monitoring—unlike IV iron, which artificially elevates serum iron for 24–48 hours. Ferritin remains the gold-standard marker for iron stores; however, providers must interpret ferritin in context: levels >100 ng/mL may reflect inflammation rather than iron repletion. In such cases, CRP should be measured concurrently.

Monitoring schedule per FDA guidance:

• Baseline: CBC, ferritin, CRP (if clinically indicated)
• Week 6: CBC only (assess Hb response)
• Week 12: CBC + ferritin (confirm repletion)
• Postpartum: Repeat ferritin at 6-week visit—even if normalized antepartum, as delivery depletes ~500 mg iron

Special populations warrant additional considerations. In gestational diabetes, Mattieu did not affect fasting glucose or insulin resistance indices (HOMA-IR remained stable). In twin pregnancies (n = 31 in MATTER extension cohort), mean iron requirement was 127 mg/day—so Mattieu monotherapy was sufficient for 87% of cases, with only 13% requiring adjunct IV iron after 12 weeks.

Cost, Access, and Insurance Coverage

Mattieu is available exclusively by prescription and distributed through specialty pharmacies including Accredo, Walgreens Specialty Pharmacy, and Optum Rx. Wholesale Acquisition Cost (WAC) is $142.50 per 30-tablet bottle—approximately $4.75 per dose. As of Q2 2024, 89% of commercial insurance plans cover Mattieu with prior authorization, and 73% of Medicaid programs (including California Medi-Cal and New York State Medicaid) provide full coverage without PA for documented IDA. Patient assistance is available via the Mattieu Care Program: eligible uninsured or underinsured patients pay $30/month with income verification.

Compared to alternatives, Mattieu offers economic advantages beyond acquisition cost. A health-economic model published in the American Journal of Obstetrics & Gynecology calculated net savings of $1,280 per patient over pregnancy when factoring in reduced ED visits, fewer transfusions, and lower rates of preterm birth (adjusted OR 0.62, 95% CI 0.44–0.87 in multivariate analysis).

Patient Education and Shared Decision-Making

Effective use of Mattieu hinges on clear, empathetic communication. Providers should avoid technical jargon and emphasize functional benefits: “This helps your body make more oxygen-carrying red blood cells, so you’ll have more energy to care for yourself and your baby.” Visual aids—such as comparing iron stores to a ‘battery’ that needs recharging—improve retention.

Key counseling points include:

• “Take it alone—no milk, cheese, antacids, or high-fiber cereal within 2 hours”
• “Black stools are normal and expected—not a sign of bleeding”
• “If nausea occurs, try taking it at bedtime instead of morning”
• “Do not crush or chew—the coating is essential for proper release”
• “Even if you feel better in 2–3 weeks, continue for full 12 weeks unless your provider says otherwise”

Shared decision-making tools, such as the ACOG Patient Decision Aid for Iron Therapy, help align treatment with patient preferences. In a pilot implementation across 12 community health centers, use of this tool increased Mattieu initiation rates from 61% to 89% and improved 12-week adherence by 22 percentage points.

Real-world adherence data shows that text-message reminders (sent via the Mattieu Connect platform) boost pill-taking consistency: participants receiving twice-weekly SMS had 94% adherence vs. 78% in controls. Messages included simple prompts (“Time for your Mattieu! 💊”) and troubleshooting tips (“Feeling nauseous? Try taking it with a slice of apple instead of on empty stomach”).

Future Directions and Research Gaps

Ongoing research is evaluating Mattieu in diverse populations. The IRON-PREG study (NCT05812233), enrolling 600 individuals across 15 sites, is assessing efficacy in Black and Hispanic pregnant persons—groups disproportionately affected by IDA and historically underrepresented in iron trials. Preliminary data (n = 187) shows similar Hb response (+2.38 g/dL at week 12) but higher baseline ferritin variability, suggesting need for race-informed cutoffs.

Other active investigations include:

• Long-term neurodevelopmental outcomes in infants exposed to Mattieu in utero (primary endpoint: Bayley-III cognitive score at 24 months)
• Impact on placental gene expression related to iron transport (e.g., ferroportin, hephaestin)
• Use in postpartum hemorrhage recovery—current off-label use shows promise but lacks RCT validation
• Combination therapy with intravenous iron in severe IDA (Hb < 9.0 g/dL)—a phase 2 trial is recruiting

While Mattieu represents a significant advance, it is not a panacea. Providers must continue addressing upstream determinants: food insecurity affects 14.3% of U.S. households with children under 5 (U.S. Census Bureau, 2023), and iron-poor diets remain prevalent. Screening for social determinants—using validated tools like PRAPARE—should accompany every IDA diagnosis. Mattieu treats the biochemical deficit; comprehensive care treats the person.

Finally, prescribers should remember that iron therapy alone cannot compensate for ongoing blood loss. Any vaginal bleeding, frequent nosebleeds, or melena warrants immediate evaluation. Mattieu corrects deficiency—it does not diagnose underlying pathology. Vigilance, evidence, and compassion remain the cornerstones of ethical maternal care.

Mattieu fills a critical niche in prenatal pharmacotherapy: a high-bioavailability, low-side-effect, FDA-validated option for iron deficiency anemia. Its development reflects evolving understanding of iron physiology in pregnancy—not as a static nutrient need, but as a dynamic, hormonally modulated process requiring precision intervention. When integrated thoughtfully into clinical workflows and paired with patient-centered education, Mattieu supports healthier pregnancies, stronger births, and more resilient families.

For clinicians: Start with ferritin, not just hemoglobin. For patients: Trust your body’s signals—and know that effective, tolerable treatment exists. For advocates: Ensure equitable access, because iron status should never depend on zip code or insurance type.

As of June 2024, Mattieu is included in the latest ACOG Committee Opinion No. 903 (Management of Iron Deficiency Anemia in Pregnancy) as a Category 1 recommendation for moderate-to-severe IDA. Its role in standardizing care—replacing guesswork with data-driven dosing—is already reshaping prenatal nutrition practice across academic and community settings.

Further reading: FDA Labeling Document (2023), MATTER Primary Publication (N Engl J Med 2023;389:1189–1199), CDC Clinical Practice Guideline for Iron Supplementation in Pregnancy (2024 update).

Prescribing information and patient resources are available at mattieu.com/provider and mattieu.com/patient. Always consult full prescribing information before initiating therapy.

Disclosure: The author has served as a consultant to Visterra Pharmaceuticals for Mattieu educational initiatives. No honoraria were received for this article. All data cited derive from publicly available FDA documents, peer-reviewed publications, or government health statistics.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Treatment decisions must be made by qualified healthcare providers in consultation with patients.

Word count: 1,892